Computational insights of 1-Guanidinosuccinimide and Benzene-ethanamine, 2,5-difluoro-β- 3,4-trihydroxy-n-methyl with MDM2 as Potential Anticancer Agent
Author:
Bako Bulus1, Etim Emmanuel E.1, Shinggu John P.1, Samuel Humphrey S.1, Moses Liberty J.1
Affiliation:
1. Federal University Wukari
Abstract
Abstract
Cancer remains a significant challenge in healthcare, spurring ongoing exploration for effective therapies. Computational methods, emerging as invaluable tools in drug discovery, have garnered attention for their cost-effectiveness and efficiency. In this study, we investigate the anticancer potential of 1-Guanidinosuccinimide and Benzene-ethanamine, 2,5-difluoro-β, 3,4-trihydroxy-n-methyl, targeting Mouse double minute 2, a critical protein in cancer pathways. Quantum chemical calculations with GAUSSIAN 09 (B3LYP; 6-311(d,p)) explored molecular structures across various solvation environments (Dimethyl Sulfoxide (DMSO) , ethanol, and methanol). Docking analysis using AutoDock Vina revealed binding to 4ZFI, with affinities of -5.9 and -6.6 kcal/mol, indicating diverse interactions. In-silico pharmacokinetics and ADMET profiling underscored favorable drug-like properties. Compound 2 emerged as a promising therapeutic candidate, showing superior binding versatility and strength. Both compounds adhere to Lipinski's rule, suggesting their potential as viable drug candidates. Further research and experimental validation are advocated to realize their therapeutic potential and expedite drug development efforts.
Publisher
Springer Science and Business Media LLC
Reference70 articles.
1. Abdullahi Bello Umar, Sagiru Hamza Abdullahi, Adamu Uzairu, Gideon Adamu Shallangwa, Sani Uba, Molecular Docking Studies of some Coumarin Derivatives as Anti-Breast Cancer agents: ComputerAided Design and Pharmacokinetics Studies. Prog. Chem. Biochem. Res, 6(3) (2023) 229–243. DOI: 10.48309/pcbr.2023.408519.1267. 2. Abdullahi SH, Uzairu A, Shallangwa GA, Uba S, Umar AB. Computational modeling, ligand-based drug design, drug-likeness and ADMET properties studies of series of chromen-2-ones analogues as anti-cancer agents, Bulletin of the National Research Centre; 2022 Dec; 46(1):1–25. 3. Adindu, E. A., Godfrey, O. C., Agwupuye, E. I., Ekpong, B. O., Agurokpon, D. C., Ogbodo, S. E., ... & Louis, H. (2023). Structural analysis, reactivity descriptors (HOMO-LUMO, ELF, NBO), effect of polar (DMSO, EtOH, H2O) solvation, and libido-enhancing potential of resveratrol by molecular docking. Chemical Physics Impact, 7, 100296. 4. Agarwal, L. P. (2007). MDM2 inhibitors: from bench to bedside. Cancer Cell, 12(3), 235–239. 5. Agoni, C., Olotu, F. A., Ramharack, P., & Soliman, M. E. (2020). Druggability and drug-likeness concepts in drug design: are biomodelling and predictive tools having their say?. Journal of molecular modeling, 26, 1–11.
|
|